GlassScriptPhysician profile
Tricia Lee
NPI 1841432457
$13,493.66
in general payments reported to CMS, 2019-2025
27 companies · $10K in 2025
The $10K reported for 2025 was more than what 89% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2021: $229 · 2022: $1,958 · 2023: $89.05 · 2024: $573 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,983 · Food and Beverage: $2,640 · Travel and Lodging: $258 · Education: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,983.00 |
| Food and Beverage | $2,639.66 |
| Travel and Lodging | $258.20 |
| Education | $144.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $5,093.39 | 2024-2025 | Xolair |
| Genzyme Corporation | $3,829.64 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $1,520.05 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $497.99 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $364.57 | 2021-2025 | Tezspire, Airsupra, Fasenra |
| Ars Pharmaceuticals Operations, INC. | $352.97 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $344.39 | 2022-2025 | |
| Optinose US, INC. | $232.99 | 2019-2025 | |
| Alk-Abello, INC | $173.91 | 2021-2025 | Neffy, Grastek, Odactra |
| Grifols USA, LLC | $154.22 | 2024-2025 | Xembify |
| Sanofi-Aventis U.S. LLC | $144.47 | 2024-2025 | |
| Biocryst US Sales Co., LLC | $133.85 | 2025 | Orladeyo |
| Amgen INC. | $118.73 | 2025 | Tezspire |
| Lilly USA, LLC | $84.38 | 2025 | Ebglyss |
| Pharming Healthcare, INC. | $57.94 | 2025 | Ruconest |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $50.54 | 2024 | Cuvitru |
| Glaxosmithkline, LLC. | $50.49 | 2025 | Trelegy Ellipta |
| Organon LLC | $46.19 | 2025 | |
| Leo Pharma INC. | $40.35 | 2024-2025 | Anzupgo, Adbry |
| Greer Laboratories, INC. | $38.89 | 2019 | |
| Paratek Pharmaceuticals, INC. | $37.89 | 2025 | Xhance |
| Galderma Laboratories, L.P. | $28.68 | 2025 | Nemluvio |
| Phadia US INC. | $23.25 | 2024 | Immunocap |
| Dermavant Sciences, INC. | $20.19 | 2024 | Vtama |
| Incyte Corporation | $18.41 | 2025 | Opzelura |
| Genentech, INC. | $18.09 | 2024 | Xolair |
| Kaleo, INC. | $17.20 | 2024 | Auvi-Q |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tricia Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.